Objectives: The aim of this study is to evaluate the prevalence and diversity of extended-spectrum b-lactamases (ESBLs) in Enterobacter cloacae clinical isolates collected from Algerian hospitals and to verify the association with qnr genes.
Introduction
b-Lactams and fluoroquinolones are the most commonly prescribed antibiotic classes. The emergence of extended-spectrum b-lactamases (ESBLs) and, more recently, of Qnr proteins conferring resistance to the broad-spectrum b-lactams by their hydrolysis and to the quinolones by protecting the topoisomerases constitutes a real concern for clinicians. b-Lactamase molecular class A includes the majority of ESBLs. At first, these were derived, essentially by the accumulation of point mutations, from TEM and SHV penicillinases. Recently, other b-lactamases emerged such as VEB, PER, GES and, in particular, CTX-M, which are the most widespread enzymes.
The Qnr proteins (QnrA-like, QnrB and QnrS) have been identified worldwide in various Enterobacteriaceae. They have a high prevalence among Asian isolates and have been frequently associated with ESBLs and plasmidic cephalosporinases.
1,2
Enterobacter cloacae is recognized as a cause of nosocomial infections, having been associated with several outbreaks, involving mutants that overproduce their chromosomal b-lactamases or, less frequently, produce an ESBL. The aim of this study was to investigate the presence of ESBLs and their association with 
Materials and methods

Bacterial isolates
Antimicrobial susceptibility and synergy testing
Antibiograms were determined on Mueller -Hinton agar by disc diffusion and interpreted according to the guidelines of the French Society of Microbiology (www.sfm.asso.fr). Escherichia coli ATCC 25922 was used as a control strain. ESBL production was screened for using the double disc synergy test (DDST) 3 with cefepime. Antibiotic discs were purchased from Bio-Rad (Marnes la Coquette, France). MICs of cefotaxime, ceftazidime, imipenem, nalidixic acid, ciprofloxacin and norfloxacin were determined by Etest for the ESBL-producing isolates. MICs of cefepime were determined for all of the isolates.
Enterobacterial repetitive consensus PCR (ERIC-PCR)
The epidemiological relationships between ESBL-producing E. cloacae isolates were analysed by ERIC-PCR using primer ERIC2. 4 Cycling conditions were as follows: 3 min at 958C; 40 cycles of 30 s at 928C, 1 min at 408C and 8 min at 728C; and final extension of 16 min at 728C. The resulting products were analysed on 1.5% agarose gels. Fingerprints were compared visually, and the patterns differing by at least one amplification band were classified as different.
Conjugation experiments and plasmid analysis
Conjugation was carried out as described previously 4 with E. coli J53-2 (Rif R) as the recipient, and transconjugants were selected on Mueller -Hinton agar containing rifampicin (250 mg/L) and cefotaxime (2.5 mg/L). Plasmid DNA was extracted using the High Pure Plasmid Isolation Kit (Roche, Mannheim, Germany), and plasmid size was estimated in comparison with plasmid size standards: pIP173 (126.8 kb) and pCFF04 (85 kb).
Characterization of ESBL-and Qnr-encoding genes
DNA was extracted from isolates with ESBL phenotypes with a QIAGEN mini kit (Qiagen, Courtaboeuf, France). These were screened for bla TEM , bla SHV , bla VEB and bla CTX-M genes by PCR, as described previously. 5 PCR amplification of qnrA, qnrB and qnrS and bla LAP-1 used specific primers and conditions. 6, 7 The ESBL and Qnr PCR products were sequenced as described previously, 4 and the nucleotide and amino acid sequences were analysed and compared by use of the BLAST computer program (National Center for Biotechnology Information).
Results and discussion
Among the 141 collected isolates, 25 (17.7%; Table 1 ) were defined as ESBL producers according to their resistance to the marker antibiotics and DDST results. MICs of cefepime ranged from 8 to .256 mg/L for ESBL producers and ,0.12 mg/L for the non-ESBL isolates. Most of the ESBL-producing isolates (20/25) showed high resistance to cefotaxime (.256 mg/L). All isolates were susceptible to imipenem (MICs 0.064 -0.5 mg/L). The quinolones tested remained active versus 80% (20/25) of the ESBL producers (Table 1) , but most producers were resistant to aminoglycosides and sulphonamides (data not shown).
ERIC-PCR typing was performed on the 25 ESBL producers from the eight hospitals scattered in three distant places in Algeria. The results showed 20 different genotypes with distinct ERIC-PCR patterns, showing clear heterogeneity in isolate genetic profiles.
ESBL phenotypes were transferred in vitro from 23 of 25 ESBL producers, in association with plasmids of 85 kb (from 20 isolates) and .150 kb (from 3 isolates). Twenty ESBL producers contained bla CTX-M genes (9 encoded CTX-M-3 and 11 CTX-M-15), four isolates harboured bla SHV-12 genes and the remaining isolate (E19) was bla VEB -positive. qnr genes were detected only in five quinolone-resistant ESBL-producing isolates; four had the QnrS1 determinant (E12, E15, E17 and E18) and one each had QnrB4 (E18) and QnrB1 (E09). Isolate E18, which harboured SHV-12 b-lactamase, was positive for both QnrB4 and QnrS1 determinants.
The 25 ESBL producers were screened for bla LAP-1 and, as shown previously, 7 only the four isolates harbouring QnrS1 were positive. This study confirmed the close association between bla LAP-1 and qnrS1 genes. None of the non-ESBL-producing E. cloacae isolates was positive for qnr alleles.
The incidence of ESBL-producing E. cloacae isolates varies according to country. Our rate of 17.7% is lower than that reported in Taiwan in 2007 (28%). 6 The use of cefotaxime and, recently, ceftazidime in Algeria could explain in part this high percentage of ESBLs. As no clonal relationship was established between the isolates, the high prevalence of ESBLs could be due to the dissemination of plasmids. The predominance of CTX-M-3 and CTX-M-15 enzymes is in accordance with previous reports in Algeria; 8 group 1 remains the only subgroup of CTX-M ESBLs found in Algeria. This is the first detection in Algeria of SHV-12, which has been described in E. cloacae in other countries. 6 The emergence of SHV-12-producing E. cloacae represents a new alert and requires more intensive monitoring. VEB-1 was found in a single E. cloacae isolate and has been reported in Providencia stuartii and Proteus mirabilis in Algeria. 9 Several studies have shown a close association between the CTX-M or SHV ESBLs and Qnr determinants (QnrA, QnrB and QnrS). 2, 6 QnrB has previously been found to be associated with CTX-M-15 in Klebsiella pneumoniae and with SHV-12 in E. cloacae. 1, 10 It was also observed recently in an Algerian E. cloacae isolate, but the allele was not sequenced. 8 QnrB1 was observed to be co-produced with CTX-M-15 in isolates of K. pneumoniae. 10 Although QnrS1 was found to be associated with SHV-12 in French isolates of E. cloacae, 9 the present study constitutes the first report of QnrS1 in isolates in Algeria. The co-expression of QnrB4 and QnrS1, as observed in isolate E18, was first reported in France in an SHV-12-producing E. cloacae. The emergence of these combinations of resistance determinants leaves us perplexed for the future of antimicrobial therapy in Algeria. This is a public health problem, which requires careful monitoring and implementation of a policy of antibiotic use.
